 |
|
|
|
|
|
|
|
|
|
|
|
1 to 5 of 5 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
LeVine III H. on LIVE DISCUSSION: Seeded Aggregation and Transmissible Proteopathy—Creepy Stuff Not Just for Prions Anymore?, Several of the proteins that aggregate in sporadic neurodegenerative disease are classified as... 29 Sep 2009.
|
|
|
 |
|
|
LeVine III H. on PAPER: Townsend M. et al., 2006, This is the latest in a series of papers evaluating the efficacy of specific inositol... 10 Jan 2007.
|
|
|
|
|
|
LeVine III H. on PAPER: Lesné S. et al., 2006, This is an impressive and important contribution. It links the appearance of a particular... 21 Mar 2006.
|
|
|
|
|
|
LeVine III H. on PAPER: Shorter J. et al., 2004, The biphasic effects of the protein-remodeling chaperone Hsp104 on the yeast self-propagating... 10 Jun 2004.
|
|
|
|
|
|
LeVine III H, Walker L. on NEWS: Amyloid Oligomer Antibody—One Size Fits All?, Over the past decade, credible evidence has gradually accrued in support of the idea that small,... 18 Apr 2003.
|
|
|
|
|
|
|
1 to 5 of 5 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
